The pharmaceutical industry is the driving force behind a number of recent high-value M&A transactions as drugs companies look for new ways to consolidate, and address patent expiration in a trend forecast to continue.
Consolidating pharma giants to drive global M&A as advisers secure major deals from Novartis and Shire
